GFH-312 is under clinical development by GenFleet Therapeutics (Shanghai) and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase I drugs for Autoimmune Disorders have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GFH-312’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GFH-312 is under development for the treatment of inflammatory conditions, peripheral artery disease, intermittent claudication, rheumatoid arthritis and autoimmune disease. It is administered orally as tablet. The drug candidate targets receptor interacting serine/threonine protein 1 (RIP1) kinase.
GenFleet Therapeutics (Shanghai) overview
GenFleet Therapeutics (Shanghai) (GenFleet Therapeutics) focuses on the discovery, development and marketing of novel small molecule drugs that target immunomodulatory pathways to enhance immunosuppression of tumors, and improve the long-term response rate of cancer drugs. The company emphasis on innovative immunology and oncology treatments. It has two manufacturing sites in China. The company has developed capabilities and expertise in the development of innovative therapeutic candidates, including both small molecules and biologics. GenFleet is the first Chinese company that moves RIPK1 inhibitor development into the clinical stage. Over ten programs are now in development and many of them have reached the clinical stages. GenFleet Therapeutics is headquartered in Shanghai, China.
For a complete picture of GFH-312’s drug-specific PTSR and LoA scores, buy the report here.